EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrating GPC3 with Other Biomarkers to Improve the Diagnosis of Early-Stage Liver Cancer

Jing Xu iD, Lin Tan, Ning Jiang, Feng Zhang, Jinling Wang, Fengcheng Li, Jin Wang, Heng Li, Lichang Chen, Olivia Mezzetti iD, Wenyu Lin iD, Shasha Li und 1 weitere

Pathogens · 2025

DOI: 10.3390/pathogens14121189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Jing Xu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. Hauptthemen laut MEDLINE: Glypicans, Liver Neoplasms, Carcinoma, Hepatocellular, Biomarkers, Tumor. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fuyang City Health Research Project, Fuyang City Department of Science and Technology, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Serum Glypican-3 (GPC3) levels in HCC patients are significantly higher than those in healthy individuals or patients with non-malignant liver diseases, making it a diagnostic marker for HCC. However, its diagnostic capability remains controversial due to its low sensitivity. The common marker AFP has limitations in terms of sensitivity and specificity, particularly in early-stage HCC. We sought to combine GPC3 detection with multi-biomarker panels to enhance sensitivity and specificity in early-stage HBV-, HCV-, and ALD-related liver cancer diagnosis. We applied receiver operating characteristic (ROC) analysis, which is used to evaluate the diagnostic performance of different biomarker tests, to develop comprehensive multi-biomarker panels that include GPC3, along with other biomarkers such as gender, age, AFP, AFP-L3%, and DCP, for assessment in the selected patients. We also applied univariate and multivariate logistic regression analysis to generate a specific diagnostic model for early HBV-induced HCC detection. We found that GPC3 levels in serum were significantly higher in HCC patients compared to CLD patients. We performed univariate and multivariate logistic regression analysis on the relevant indicators of early HCC to establish a new GDATA model for diagnosing early HCC. The new model included five indicators of early HCC: GPC3, DCP, AFP-L3%, TBIL and age. The diagnostic efficacy was better than that of GPC3, AFP, DCP and AFP-L3 alone. The diagnostic accuracy of the GDATA model for early HCC was significantly higher than that of the GALAD model or single indicators alone. The GDATA model thus provides a new promising diagnostic strategy for early HCC detection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlypicansLiver NeoplasmsCarcinoma, HepatocellularBiomarkers, TumorEarly Detection of CancerHumansMaleFemaleMiddle AgedROC CurveAgedAdultSensitivity and Specificityalpha-Fetoproteins

Stichwörter der Autor:innen

Des-gamma-carboxy prothrombin (DCP)GALADalpha-fetoprotein (AFP)glypican-3 (GPC3)hepatitis B virus (HBV)hepatocellular carcinoma (HCC)

Substanzen

GlypicansGPC3 protein, humanBiomarkers, Tumoralpha-Fetoproteins

Autor:innen und Institutionen

  • Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
  • Department of Hepatology, The Second People's Hospital of Fuyang City, Fuyang 236015, China.
  • Department of Clinical Laboratory, The Second People's Hospital of Fuyang City, Fuyang 236015, China.
  • Department of Hepatobiliary Surgery, The Second People's Hospital of Fuyang City, Fuyang 236015, China.
  • Liver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

ORCID-Profile: Jing Xu, Olivia Mezzetti, Wenyu Lin

Förderung

  • Fuyang City Health Research Project
  • Fuyang City Department of Science and Technology
  • National Natural Science Foundation of China
  • Fuyang Municipal Special Fund for Clinical Medical Research Transformation
  • Fuyang Fuyang Municipal Special Fund for Clinical Medical Research Transformation
  • Natural Science Foundation of Education Department of Anhui Province
  • Anhui Provincial Special Fund for Clinical Medical Research Transformation

Zitieren

APA

Xu, J., Tan, L., Jiang, N., Zhang, F., Wang, J., Li, F., Wang, J., Li, H., Chen, L., Mezzetti, O., Lin, W., Li, S., & Gao, Y. (2025). Integrating GPC3 with Other Biomarkers to Improve the Diagnosis of Early-Stage Liver Cancer. Pathogens. https://doi.org/10.3390/pathogens14121189

Vancouver

Xu J, Tan L, Jiang N, Zhang F, Wang J, Li F, et al. Integrating GPC3 with Other Biomarkers to Improve the Diagnosis of Early-Stage Liver Cancer. Pathogens. 2025. doi:10.3390/pathogens14121189

BibTeX
@article{Xu2025,
  author = {Xu, Jing and Tan, Lin and Jiang, Ning and Zhang, Feng and Wang, Jinling and Li, Fengcheng and Wang, Jin and Li, Heng and Chen, Lichang and Mezzetti, Olivia and Lin, Wenyu and Li, Shasha and Gao, Yufeng},
  title = {Integrating GPC3 with Other Biomarkers to Improve the Diagnosis of Early-Stage Liver Cancer},
  journal = {Pathogens},
  year = {2025},
  doi = {10.3390/pathogens14121189}
}
Kostenlos starten →